Notice: This company has been marked as potentially delisted and may not be actively trading. (BIOA) (BIOA) Competitors Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsCompetitorsHeadlinesInsider TradesOwnershipTrends BIOA vs. ACAD, JANX, ZLAB, AMRX, CPRX, GERN, BLTE, LBPH, IDYA, and ARWRShould you be buying (BIOA) stock or one of its competitors? The main competitors of (BIOA) include ACADIA Pharmaceuticals (ACAD), Janux Therapeutics (JANX), Zai Lab (ZLAB), Amneal Pharmaceuticals (AMRX), Catalyst Pharmaceuticals (CPRX), Geron (GERN), Belite Bio (BLTE), Longboard Pharmaceuticals (LBPH), IDEAYA Biosciences (IDYA), and Arrowhead Pharmaceuticals (ARWR). These companies are all part of the "pharmaceutical preparations" industry. (BIOA) vs. ACADIA Pharmaceuticals Janux Therapeutics Zai Lab Amneal Pharmaceuticals Catalyst Pharmaceuticals Geron Belite Bio Longboard Pharmaceuticals IDEAYA Biosciences Arrowhead Pharmaceuticals (BIOA) (NYSE:BIOA) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and community ranking. Do analysts rate BIOA or ACAD? (BIOA) currently has a consensus price target of $42.33, indicating a potential upside of 121.18%. ACADIA Pharmaceuticals has a consensus price target of $25.56, indicating a potential upside of 56.15%. Given (BIOA)'s stronger consensus rating and higher possible upside, equities analysts plainly believe (BIOA) is more favorable than ACADIA Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score (BIOA) 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00ACADIA Pharmaceuticals 0 Sell rating(s) 6 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.65 Is BIOA or ACAD more profitable? ACADIA Pharmaceuticals has a net margin of 13.83% compared to (BIOA)'s net margin of 0.00%. ACADIA Pharmaceuticals' return on equity of 25.83% beat (BIOA)'s return on equity.Company Net Margins Return on Equity Return on Assets (BIOA)N/A N/A N/A ACADIA Pharmaceuticals 13.83%25.83%14.71% Which has better earnings & valuation, BIOA or ACAD? (BIOA) has higher earnings, but lower revenue than ACADIA Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio(BIOA)N/AN/AN/AN/AN/AACADIA Pharmaceuticals$726.44M3.75-$61.29M$0.7820.99 Does the media prefer BIOA or ACAD? In the previous week, ACADIA Pharmaceuticals had 22 more articles in the media than (BIOA). MarketBeat recorded 23 mentions for ACADIA Pharmaceuticals and 1 mentions for (BIOA). ACADIA Pharmaceuticals' average media sentiment score of 0.09 beat (BIOA)'s score of 0.00 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment (BIOA) 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ACADIA Pharmaceuticals 6 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals and insiders hold more shares of BIOA or ACAD? 96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. 1.8% of (BIOA) shares are held by company insiders. Comparatively, 28.3% of ACADIA Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the MarketBeat Community believe in BIOA or ACAD? ACADIA Pharmaceuticals received 602 more outperform votes than (BIOA) when rated by MarketBeat users. However, 73.30% of users gave (BIOA) an outperform vote while only 73.20% of users gave ACADIA Pharmaceuticals an outperform vote. CompanyUnderperformOutperform(BIOA)Outperform Votes29173.30% Underperform Votes10626.70% ACADIA PharmaceuticalsOutperform Votes89373.20% Underperform Votes32726.80% SummaryACADIA Pharmaceuticals beats (BIOA) on 10 of the 13 factors compared between the two stocks. Ad Weiss RatingsTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.This could be his favorite coin. Get (BIOA) News Delivered to You Automatically Sign up to receive the latest news and ratings for BIOA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BIOA vs. The Competition Export to ExcelMetric(BIOA)Pharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$686.17M$6.59B$5.21B$20.34BDividend YieldN/A8.14%5.53%3.48%P/E RatioN/A6.7882.8840.70Price / SalesN/A357.041,246.7619.01Price / CashN/A53.8240.9121.67Price / BookN/A10.617.204.72Net IncomeN/A$153.27M$119.63M$987.19M (BIOA) Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BIOA(BIOA)1.563 of 5 stars$19.14+3.8%$42.33+121.2%+149,431.3%$686.17MN/A0.00N/AACADACADIA Pharmaceuticals3.7145 of 5 stars$16.37+1.2%$25.56+56.2%-25.6%$2.72B$929.24M21.04510Insider TradeAnalyst RevisionNews CoverageJANXJanux Therapeutics3.9316 of 5 stars$50.31+8.2%$67.70+34.6%+452.3%$2.64B$8.08M-43.0030Analyst ForecastNews CoverageZLABZai Lab2.9609 of 5 stars$26.43+2.8%$52.50+98.6%-3.9%$2.63B$266.72M-9.282,175AMRXAmneal Pharmaceuticals3.2246 of 5 stars$8.39+0.8%$10.00+19.2%+88.5%$2.60B$2.68B-12.347,700Insider TradeNews CoverageCPRXCatalyst Pharmaceuticals4.7111 of 5 stars$21.48+1.7%$31.14+45.0%+55.0%$2.56B$460.48M17.95167GERNGeron3.574 of 5 stars$4.07+1.2%$7.05+73.2%+108.7%$2.46B$240,000.00-12.72141BLTEBelite Bio1.8341 of 5 stars$80.23-2.7%$89.00+10.9%+112.9%$2.46BN/A-72.2820LBPHLongboard Pharmaceuticals1.7786 of 5 stars$59.80+0.1%$59.56-0.4%+1,358.5%$2.34BN/A-26.8220Positive NewsIDYAIDEAYA Biosciences4.1879 of 5 stars$26.79+0.7%$53.67+100.3%-15.2%$2.32B$3.92M-11.5080High Trading VolumeARWRArrowhead Pharmaceuticals3.6338 of 5 stars$18.54+1.4%$45.33+144.5%-36.0%$2.30B$240.74M-3.97400Upcoming EarningsAnalyst ForecastNews Coverage Related Companies and Tools Related Companies ACADIA Pharmaceuticals Alternatives Janux Therapeutics Alternatives Zai Lab Alternatives Amneal Pharmaceuticals Alternatives Catalyst Pharmaceuticals Alternatives Geron Alternatives Belite Bio Alternatives Longboard Pharmaceuticals Alternatives IDEAYA Biosciences Alternatives Arrowhead Pharmaceuticals Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:BIOA) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding (BIOA) Please log in to your account or sign up in order to add this asset to your watchlist. Share (BIOA) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.